2023-06-272023-06-272019-05LOURINHO, Luan Leonardo Corrêa; COUTO, Rafaella Abrahão do. Comparação da altura entre pacientes com puberdade precoce dependente de gonadotrofinas após 2 anos de tratamento com aGnRH isoladamente e em associação com GH. Orientadora: Karem Mileo Felício. 2019. 45 f. Trabalho de Curso (Bacharelado em Medicina) – Faculdade de Medicina, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, 2019. Disponível em: https://bdm.ufpa.br:8443/jspui/handle/prefix/5792. Acesso em: .https://bdm.ufpa.br/handle/prefix/5792Gonadotrophin-dependent precocious puberty (GDPP) is a rare condition, more common in girls, in which occurs the development of secondary sexual characters at inappropriate age, associated with the acceleration of growth, as well as bone age, drastically impairing height the child's ultimate goal. Treatment with gonadotrophin releasing hormone (aGnRH) analogues for bone age stabilization is well established in the literature, especially in cases of early diagnoses and treatment is started before the age of six years. Objective: The present study aimed to evaluate if the associated use of growth hormone (rGH) was superior to the isolated use of aGnRH in relation to improving predicted height. Method: Retrospective longitudinal study of patients’ medical records with precocious puberty dependent on gonadotropins attended at the endocrinology clinic of the University Hospital João de Barros Barreto. After clinical, laboratory or imaging diagnosis of GDPP, the patients were divided into two groups according to the type of treatment they underwent, and the data was analyzed descriptively and analytically. Results: The group treated with aGnRH and rGH combination (n = 27) was smaller than the group treated with aGnRH alone (n = 88), however, in the associated treatment group, the proportion of boys was higher (29%) when compared to the group with only analogues (5%). In addition, these patients had a lower bone age increase with a mean height increase of 14.1 cm over a 2-year follow-up versus 11.1 cm in the aGnRH group alone in the same period. In addition, the predicted height in the rGH + aGnRH group increased significantly by an average of 7.4 cm in 2 years of treatment, while the group in use of the isolated analog also improved, but only 3.7 cm after 2 years of pubertal block. Conclusion: Both the treatment with the isolated analogue and in combination with growth hormone were beneficial to improve the predicted height, but in the group with associated drugs, a greater benefit was observed, even in patients who started treatment late, Thus, despite the high cost and the need for further studies, the use of growth hormone should be considered at least in patients with late diagnosis of precocious gonadotrophin-dependent puberty.Acesso AbertoPuberdade precoceHormônio liberador de gonadrotopinas agonistasHormônio de crescimentoEstaturaPubertyPrecociousGonadotropin-Releasing hormone agonistsGrowth hormoneBody HeighCNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::ENDOCRINOLOGIATrabalho de Curso - Graduação - Monografia